4/A: Phathom CFO Reports 144K RSU Grant Amendment

Phathom Pharmaceuticals' Chief Financial and Business Officer, Sanjeev Narula, reported the acquisition of 144,000 restricted stock units via an amended SEC filing.

Summary

• Sanjeev Narula, Chief Financial & Business Officer of Phathom Pharmaceuticals, Inc. (PHAT), reported the acquisition of 144,000 shares of Common Stock.
• The acquisition represents restricted stock units (RSUs) granted on October 6, 2025.
• One-third (1/3) of the total RSUs will vest on each of the first three anniversaries of October 6, 2025, contingent on Mr. Narula's continued service.
• Each RSU represents a contingent right to receive one share of Phathom Pharmaceuticals' common stock.
• This filing is an amendment (Form 4/A) to report a transaction that was inadvertently omitted from the original Form 4 filed on October 7, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the transaction itself is routine executive compensation, it signifies continued insider ownership and alignment of management's interests with shareholders. The amendment for an omission is a minor administrative correction.

Positives

• The grant of restricted stock units aligns the Chief Financial & Business Officer's long-term interests with those of the shareholders.
• Increased insider ownership through equity grants can signal management's confidence in the company's future performance.

Industry Context

The grant of restricted stock units to a key executive like the Chief Financial & Business Officer is a standard practice in the pharmaceutical and biotechnology industries. It serves as a long-term incentive, aiming to retain talent and align executive performance with shareholder value creation, which is crucial in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• Restricted Stock Unit (RSU) grants are a common form of equity compensation for executives across various industries, including pharmaceuticals, aligning management's financial interests with the company's long-term stock performance.
• The vesting schedule over three years is typical for such grants, designed to incentivize continued service and sustained performance, comparable to practices at other publicly traded biotech and pharma companies.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Financial & Business Officer's long-term financial incentives with shareholder value creation, potentially fostering greater commitment to the company's success.
• Employees: Executive compensation practices, including RSU grants, can influence overall compensation philosophy and morale within the company.

Next Steps

• One-third of the granted RSUs will vest on October 6, 2026, subject to continued service.
• One-third of the granted RSUs will vest on October 6, 2027, subject to continued service.
• The final one-third of the granted RSUs will vest on October 6, 2028, subject to continued service.

Key Dates

Recommendation

This Form 4/A filing details a routine executive RSU grant and an administrative correction for an omitted transaction. While the insider acquisition is a positive signal for management alignment, it does not provide new fundamental information or significant catalysts to warrant a change in investment recommendation based solely on this filing. It reinforces a 'hold' stance for investors already considering the company's broader financial and strategic position.

Keywords

Phathom Pharmaceuticals, PHAT, Sanjeev Narula, Restricted Stock Units, RSU grant, Insider transaction, Executive compensation, SEC Form 4/A